DRUG
Bright Minds BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
A robust positive BMB-101 readout and subsequent partner interest would validate mechanism and drive rapid re-rating toward premium targets; analysts' high cases reflect successful clinical and commercial execution.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +7.0.
What can break
Insufficient cash runway leading to dilution
Momentum
55
Value
41
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $88.00 · Bull $140.00 · Bear $60.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $146.61
Why
Momentum55 · Δ7d +0.8
Value41 · Δ7d +0.1
Sentiment75 · Δ7d +7.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
55
34% active weight
Current posture
7d trendSoftening
Δ7d
+0.8
Δ21d
-30.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
75
33% active weight
Current posture
7d trendImproving
Δ7d
+7.0
Δ21d
+16.4
Why this grade
Composite grade B. Momentum 54.5 / Value 41.1 / Sentiment 75.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$792.96M
Beta
-0.59
Shares Out
7.79M
P/E (TTM) · Derived
-80.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-111.25
Rev YoY
-
EPS YoY
-243.7%
Gross Margin
-
Op Margin
-
Net Debt
-$59.22M
Current Ratio
36.10
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology